Study of Letrozole in Recurrent Gliomas
The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.
Trial Details
- NCT ID
- NCT03122197
- Phase
- EARLY_PHASE1
- Sponsor
- University of Cincinnati
- Status
- RECRUITING
- Cancer Type
- Brain Cancer
- Interventions
- Letrozole Oral Tablet
- Temozolomide
- Locations (sample)
- Cincinnati, Ohio, United States|39.12711,-84.51439
Key Eligibility Criteria
- Radiographically, histologically or cytologically confirmed recurrent brain high grade glioma with plan for resection or biopsy.
- \- Inclusion #1 for Sub-study Only: Radiographically, histologically or cytologically confirmed recurrent brain high grade glioma.
- Age \>18 years.
- ECOG performance status 0 -2 (Karnofsky \>60%, see Appendix A).
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Brain Cancer Trials on Trialify →